



Fact Sheet

Q3 2015


Issued November 2015 | ir.tevapharm.com

CONTACT INFORMATION: Kevin Mannix | Tel: +1 (215) 591-8912 Email: kevin.mannix@tevapharm.com Ran Meir | Tel: +1 (215) 519 - 3033 Email: Ran.Meir@tevapharm.com


Company Overview

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2014 amounted to \$20.3 billion, and approximately 4.8 billion in Q3 2015. For more information, visit www.tevapharm.com.


Operating Income⁽¹⁾ and Cash Flow: YTD 2015




Stock Chart: (Rolling 12 months as of October 30 2015)




Net Revenues (USD m)




Net Income (non GAAP¹) (USD m)



Earnings Per Share (non GAAP)⁽¹⁾ (USD)



Dividends Per Share (USD)



(1) See non GAAP reconciliation in our report for the (3rd Quartes)

Q3 2015 Business Highlights

Generics

- Gross profit margin for our generic medicines segment in the third quarter of 2015 increased to 45.6%, from 44.3% in the third quarter of 2014.
- The generic medicines segment generated profit of \$578 million in the third quarter of 2015, an increase of 4% compared to the third quarter of 2014.



Specialty

- U.S. specialty medicines revenues amounted to \$1.7 billion, up 11% compared to the third quarter of 2014
- In the United States, sales of Copaxone® amounted to \$878 million, an increase of 10% compared to the third quarter of 2014

On July 27, 2015, we announced that we had entered into a definitive agreement to acquire Allergan Generics for total consideration of \$40.5 billion in cash and Teva shares value at \$6.75 billion. Teva expects the acquisition to close in the 1st quarter of 2016.


Revenues by Markets and Segments

Q3 - 2015



Profit** by Segment

Q3 - 2015



* Other activities include our OTC business with P&G, distribution services primarily in Israel and Hungary, and sales of medical devices

** Profit consists of gross profit, less S&M and R&D expenses related to the segment. Segment profitability does not include G&A expenses, amortization and certain other items.

Teva Specialty pipeline

Phase 1	Phase 2	Phase 3	Registration
TV-46139 (abuse deterrent) Pain	TV-45070 Topical Neuropathic pain	TV-46763 (abuse deterrent) Pain	Vantrela ER Hydrocodone (abuse deterrent) US Pain
SD-809 Tourette syndrome	TEV-48125 (anti CGRP) Chronic and episodic migraine	Laquinimod Multiple sclerosis (relapsing remitting)	Copaxone® 40mg 3w ROW Multiple sclerosis
SD-560 Idiopathic pulmonary fibrosis	Laquinimod Multiple sclerosis (progressive forms)	SD-809 Tardive dyskinesia	SD-809 Huntington Disease
Fluticasone Salmeterol (MDI) EU Asthma, COPD	Laquinimod Huntington disease	Fluticasone Propionate MDPI Asthma	Reslizumab IV Asthma
TEV-46017 (tidal inhaler) COPD	Pridopidine Huntington disease	Fluticasone Salmeterol MDPI Asthma	Fluticasone Salmeterol Spiromax EU Asthma, COPD
TEV-48107 (tidal inhaler) COPD	CEP-41750 (mesenchymal precursor cell) Acute myocardial infarction	QVAR® (BAI) US Asthma	Fluticasone Salmeterol Spiromax EU Asthma COPD
TEV-90110 HIV	TV-1106 (Albutropin) – peds Growth hormone deficiency	Reslizumab SC Asthma	Bendamustine Rapid Infusion* CLL, NHL
TEV-90111 HIV		CEP-41750 (mesenchymal precursor cell) Chronic heart failure	
TEV-90112 HIV		TV-1106 (Albutropin) – adults Growth hormone deficiency	
TEV-90113 HIV			

■ Migraine & Pain
 ■ Movement Disorders & Neurodegeneration
 ■ Respiratory
 ■ Other

* Filed by Eagle Pharmaceutical, commercialized by Teva
 Note: Pipeline is correct as of Oct 2015. Phase 1 includes also projects designated for IND filing.